Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Dexcom : Announces Upcoming Conference Presentation

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2019 | 09:02am EST

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

  • Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Stephens Nashville Investors Conference in Nashville, TN on Wednesday, November 13, 2019 at 9:45 AM (CT). The presentation, which will occur live at the Omni Nashville Hotel, will be concurrently webcast.

The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to “Events and Presentations.”

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for use by people with diabetes and by healthcare providers.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on DEXCOM, INC.
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
02/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
02/13DEXCOM : Reports Fourth Quarter and Fiscal Year 2019 Financial Results
BU
02/10DEXCOM, INC. : annual earnings release
01/21DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time
BU
01/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
More news
Financials (USD)
Sales 2020 1 782 M
EBIT 2020 237 M
Net income 2020 182 M
Finance 2020 37,7 M
Yield 2020 -
P/E ratio 2020 157x
P/E ratio 2021 106x
EV / Sales2020 15,0x
EV / Sales2021 12,1x
Capitalization 26 716 M
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 287,33  $
Last Close Price 291,68  $
Spread / Highest target 8,34%
Spread / Average Target -1,49%
Spread / Lowest Target -36,6%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical, Regulatory Affairs & Quality
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.33.35%26 716
MEDTRONIC PLC-0.70%151 053
BAXTER INTERNATIONAL INC.11.41%47 083
HOYA CORPORATION1.36%34 487
ZIMMER BIOMET HOLDINGS6.91%32 755
TERUMO CORPORATION1.41%25 810